CD3-binding (T cell engaging) immune stimulating antibody-based therapies

Learning Objectives

  • Understand the pharmacology of T cell engaging molecules and the spectrum of safety liabilities resulting from their mode of action  
  • Specific challenges for in vivo nonclinical safety studies performed with TCEs i.e. sampling schedules, cytokine release, ADAs, on-target off-tumor toxicity 
  • Typical nonclinical pharmacology and toxicology package required to support FIH studies and BLA submission 
  • Current hot topics in the development of TCEs i.e. requirement for 3-month studies, studies required for well-characterized targets, use of surrogate molecules, transgenic animal models 
Course summary
Available credit: 
  • 1.00 Participation
Course opens: 
09/28/2022
Course expires: 
09/30/2027
Cost:
$25.00
Rating: 
0

Benno Rattel

Available Credit

  • 1.00 Participation

Price

Cost:
$25.00
Please login or register to take this course.